Wepresent findings in the ninth known Japanese family with lecithin : cholesterol acyltransferase (LCAT) deficiency. A 54-year-old man (proband) and his 58-year-old brother presented with corneal opacity. Both subjects showed a marked decrease in serum high density lipoprotein (HDL)-cholesterol and in the cholesteryl ester ratio. Although apo A-I and A-II were low, apo E tended to be high. Serum LCATactivity and mass were not detectable. Urinary examination showed microhematuria or proteinuria. Renal function was normal and no anemia was demonstrated, but blood smears showed poikilocytosis with target cells. The serum LCATactivity of the proband's three sons, obligate heterozygotes of LCATdeficiency, was about one-half the normal level, and HDL-cholesterol and apo A-I levels were low normal. (Internal Medicine 33: 677-682, 1994) 
Introduction
Lecithin : cholesterol acyltransferase (LCAT; EC 2.3. 1.43) is a glycoprotein synthesized by hepatocytes and secreted into the plasma. It forms a complex with HDLparticles and catalyzes the formation of cholesteryl esters and lysolecithin by the preferential translocation of unsaturated sn-2 fatty acids from lecithin to the 3B-hydroxy group of cholesterol. Cholesteryl esters that are formed in this enzymatic reaction are subsequently transferred into the hydrophobic core of HDLparticles (1 , 2) . Consequently, LCATbrings about the maturation of the HDLparticles; it mediates an essential step in the reverse cholesterol transport process wherebyexcess cellular cholesterol is transferred to the liver, from which it can leave the body by bile acid formation or direct secretion into the bile. This paper describes the ninth Japanese family with LCAT deficiency, the memberswere two homozygotesand three obligate heterozygotes. The present work was presented at the annual meeting of the Japan Atherosclerosis Society held in Fukuoka on May 21, 1993 (7).
Methods
Lipoprotein analysis
Blood was drawn from each subject after an overnight fast. Phospholipids extracted from serumwere separated by thinlayer chromatography on a silica gel-sintered stick with chloroform and detected by a flame ionization detector (9, 10). Lipoprotein (a) was measured by ELISA. Agarose gel electrophoresis was carried out as described by Noble (1 1) and lipoprotein X was examined as described by Crlomset et al (12). Electron microscopy of HDLparticles was performed using Formvar-coated grids and 1%sodium phosphotungstate as a negative stain (13). Serum LCATactivity was measured by a sensitive artificial substrate method, using proteoliposomes containing apo A-I as a substrate (14) . LCATmass was determined by radioimmunoassay, using rabbit anti-human LCAT antibody (15) .
Case Histories and Results
Case 1 (O.T., the proband), a 54-year-old Japanese male, was born in 1938. When he was 24 years old, he lost his right forearm in an accident. In 1992, he visited our clinic with complaints ofgastrointestinal trouble; because of corneal opacities, he was suspected of having LCATdeficiency. Physical examination revealed no clinical abnormalities except for corneal opacities with corneal rings (Fig. 1 ) and amissing right forearm.
His corneal opacities had been noticed from childhood. Laboratory findings are shown in Table 1 . Urinary examination showed microscopic hematuria and occasional small round cells and hyaline casts in the sediment, but no proteinuria. Serum urea nitrogen and creatinine were within normal limits.
No anemia was demonstrated, but the blood smear showed poikilocytosis with target cells (Fig. 2) . In vitamin A fractions, serum retinol was normal, but retinyl palmitate was increased. Serum concentrations of vitamin E fractions were normal. There was no significant decrease of serum haptoglobin whose gene position (16q22) is close to that of LCAT, and the phenotype was 2-2.
Serum TC was 135 mg/dl, the cholesteryl ester ratio (CE) was 9%, and serum HDL-C was 8.9 mg/dl ( Table 2) . Although apo A-I and A-II were low, apo E tended to be high. Serum phospholipid analysis demonstrated 94.6% lecithin and 5.4%
sphingomyelin, but no lysolecithin was detectable. Serum
LCATactivity and mass were not detectable, suggesting that the subject is a homozygote for LCATdeficiency. The results of agarose gel electrophoresis are shown in Fig. 3 . Lipoprotein X was demonstrated (Fig. 4) . LDLwas rich in TG andPL ( Table   Table 1 3). HDL2-C was slightly decreased and HDL3-C was severely decreased.
Case 2 (K.T.), a 58-year-old Japanese male, is the elder brother of Case 1 (Fig. 5) . At the age of48 years, he underwent surgery because of subarachnoid hemorrhage. He has been under a physician's care due to diabetes mellitus for several years. Physical examination showed corneal opacities and rings similar to those of Case 1. Marked proteinuria was demonstrated, although the results of renal function tests were normal. Serum LCATmass and activity were not detectable, suggesting that Case 2 was also homozygous for LCATdeficiency ( Table  2 ). The ultracentrifugally separated HDLfraction showed rouleaux formation of discoid HDLparticles (Fig. 6) . Family background. The parents of Cases 1 and 2 were first cousins who were born in Nakatsugawa City, Gifu Prefecture, Japan (Fig. 5) . The LCATactivity of the wife and three sons of Case 1 was determined ( Table 2 ). The LCAT activity of the sons, who were all obligate heterozygotes, was low, about onehalfthe normal level. The LCATactivity of the proband's wife was normal. HDL-Cand apo A-I levels of the sons were low normal, between those of the homozygotes and normal (Case 6). Lipoprotein fractions of a heterozygote, Case 4, were normal, except that HDL2-and HDL3-Clevels were low normal (Table 3 ).
Discussion
Several disorders that affect lipoprotein metabolism are associated with HDLdeficiency and corneal opacification, including Tangier disease (16), LCAT deficiency (4, 17), fish eye disease (17, 18) , apo A-I, C-III deficiency (19) , apo C-III, A-I, A-IV deficiency (20) , fish eye-like dyslipoproteinemia (21) , and specific apo A-I variants (22, 23) . Although the degree of corneal opacity ranges from mild cloudiness in Tangier disease to severe opacification in fish eye disease, it does not correlate with the degree of reduction of HDL.Despite the marked reduction in HDL,many of these conditions are not associated with premature atherosclerosis. There was no evidence of ischemic heart disease or other atherosclerotic disorders in the present family. by membrane abnormality due to HDLdysfunction; (e) low serum cholesteryl ester ratio. These findings are observed only in homozygotes, not in heterozygotes. Proteinuria and anemia are common. Eventually, renal function deteriorates and dialysis or renal transplantation maybecomenecessary. The present cases had normal renal function, but Case 1 showed microhematuria and Case 2 showed marked proteinuria. They are now being followed at Nakatsugawa Municipal Hospital. At least nine independent families with LCATdeficiency have been reported from Japan, including the present family (6, (24) (25) (26) (27) (28) (29) (30) . Amongthem, the molecular defects of four families wererecently analyzed by polymerase chain reaction and subsequent direct sequencing (3 1-33) . Their results show that distinct mutations cause differences in plasma LCATactivity and LCAT mass, leading ultimately to differential phenotypic expression of familial LCATdeficiency. The consequence of molecular defects in the LCATgene is (a) a null allele, (b) a synthesis defect, (c) an enzyme with impaired binding to both HDL and VLDL-LDL, or (d) a functionally inactive or hypoactive enzyme (34, 35). In the two homozygous cases in the present family, LCAT mass and activity were not detectable, suggesting that they are so-called null type cases. In the three heterozygotes, LCAT activity was about halfofnormal level. In some early cases from Japan, only serum or plasma LCATactivity was measured, but in other cases LCATmass was also determined. Amongthem, a case reported by Muranoet al (28) is also a null type, demonstrating almost negligible LCATmass and activity. Gene analysis of the present family is now in progress in one of our laboratories (E. Maeda). 
